• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TIVOZANIB Drug Record

  • Summary
  • Interactions
  • Claims
  • TIVOZANIB chembl:CHEMBL1289494 ApprovedAntineoplastic

    Alternate Names:

    KRN-951
    TIVOZANIB
    KIL-8951
    KIL8951
    ASP-4130
    AV-951
    FOTIVDA
    VEGFR TYROSINE KINASE INHIBITOR IV
    drugbank:11800
    chembl:CHEMBL1289494
    pubchem.compound:9911830
    chemidplus:475108-18-0

    Drug Info:

    FDA Approval not approved
    Drug Class Small molecule
    Drug Indications antineoplastic agent
    Drug Class Kinase Inhibitors
    (5 More Sources)

    Publications:

    Proia et al., 2015, 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity., Mol. Cancer Ther.
    Friedman et al., 2015, Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment., PLoS ONE
  • TIVOZANIB   FLT1

    Interaction Score: 0.77

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Novel drug target Established target
    Trial Name AV-951

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD

  • TIVOZANIB   FLT4

    Interaction Score: 0.74

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name AV-951
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD

  • TIVOZANIB   KDR

    Interaction Score: 0.49

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name AV-951
    Novel drug target Established target
    Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD

  • TIVOZANIB   BRAF

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy PLX4720 + Tivozanib
    Indication/Tumor Type melanoma
    Response Type sensitive

    PMIDs:
    26461489


    Sources:
    JAX-CKB

  • TIVOZANIB   ERBB2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy 23814 + Tivozanib
    Indication/Tumor Type breast cancer
    Response Type sensitive

    PMIDs:
    25995436


    Sources:
    JAX-CKB

  • TIVOZANIB   YES1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MyCancerGenome: TIVOZANIB

    • Version: 20-Jun-2017

    Alternate Names:
    KRN951 Development Name
    AV-951 Development Name
    TIVOZANIB Generic Name

    Drug Info:
    Drug Class Kinase Inhibitors

    Publications:

  • TdgClinicalTrial: TIVOZANIB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small molecule
    FDA Approval not approved

    Publications:

  • JAX-CKB: Tivozanib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Friedman et al., 2015, Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment., PLoS ONE
    Proia et al., 2015, 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity., Mol. Cancer Ther.

  • TALC: TIVOZANIB

    • Version: 12-May-2016

    Alternate Names:
    TIVOZANIB Primary Drug Name
    TIVOZANIB Drug Generic Name
    TIVOPATH Drug Trade Name

    Drug Info:

    Publications:

  • DTC: TIVOZANIB

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1289494 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Tivozanib

    • Version: 2020.06.01

    Alternate Names:
    D0W7JZ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1289494

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1289494

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: TIVOZANIB

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21